Citalopram (HBr)

Citalopram (HBr) is antidepressant drug and used to treat depression.


Adult Dose
Dose: 10 to 20 mg
Single Dose: 15 (15)
Frequency: 24 hourly
Route: PO
Instructions:
Neonatal
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Paedriatic
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Characteristics
citalopram hydrobromide, citalopram hydrobromide are the derivatives of Citalopram (HBr). It is of Synthetic origin and belongs to Benzofuran. It belongs to Antidepressant pharmacological group.The Molecular Weight of Citalopram (HBr) is 405.30. Its pKa is 9.5.
Contraindications
Citalopram (HBr) is contraindicated in conditions like Mania.
Effects
The severe or irreversible adverse effects of Citalopram (HBr), which give rise to further complications include Bradycardia.Citalopram (HBr) produces potentially life-threatening effects which include Hypertensive crises, Manic attacks. which are responsible for the discontinuation of Citalopram (HBr) therapy.The signs and symptoms that are produced after the acute overdosage of Citalopram (HBr) include Convulsions, Respiratory depression, Respiratory depression, Hypoxia.The symptomatic adverse reactions produced by Citalopram (HBr) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Insomnia, Dry mouth, Sedation, SweatingX, Tremor, SomnolenceX, Xerosis, Dry mouth, dizziness, increased cysetile weight again.
Indications
Citalopram (HBr) is primarily indicated in conditions like Alcohol dependence, Depression, Obsessive-compulsive disorders, Panic disorders.
Interactions
Citalopram (HBr) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholCimetidine (HCl)Iproniazid PhosphateTheoretical potential for IPRONIAZID increasing the SEROTONERGIC effect of CITALOPRAM..MajorMethotrimeprazine (Maleate)MethylamphetamineSeveral case reports suggest that patients treated with serotonin reuptake inhibitors (SRIs) may exhibit an increased sensitivity to sympathomimetic agents. The mechanism of interaction is unclear. The reaction has been reported when fluoxetine was used concomitantly with phentermine, amphetamine, or phenylpropanolamine. Additionally, some sympathomimetic agents (e.g., amphetamines) may possess serotonergic activity and should generally not be administered with SRIs because of the additive risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A receptorsModerateNaratriptanConcurrent use is not recommended, but dosages should be adjusted if concurrent use is required.ParegoricCentral nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.ModerateDuring concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them. Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.PhenelzinePimozideSumatriptanTrimeprazine (Tartrate)VORICONAZOLEVoriconazole may increase the serum concentration of citalopram by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of citalopram if voriconazole is initiated, discontinued or dose changed.Vortioxetineincreases the level of vortioxetinemonitor closely, use alternative These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Urinanalysis
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tab Store in a well closed container, Below 25°C. Protect from Moisture.
Warnings
Citalopram should be used with caution in hepatic or severe renal impairment, during pregnancy and lactation.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.